Tagged with Lilly,

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Pharma The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s rich pipeline is set to boost growth in new areas over the next few years. We interviewed you during your…

Pharma With a large and growing population, and significant domestic health needs, Lilly Egypt general manager Ozkan Ozdogan sees many opportunities for various stakeholders to serve patients, and is focusing on improving healthcare practitioners’ ability to better train diabetes patients to manage their condition.    After 14 years with Lilly Turkey in…

Pharma Medical Union Pharmaceuticals (MUP) acquired Lilly’s Egyptian human insulin vial manufacturing facility in early 2015. Managing Director Ahmed Kelani discusses the national significance of this acquisition given Egypt’s high prevalence of diabetes, and how the transferred technology will support MUP’s ambition to become a leading pharmaceutical manufacturer in the region.…

Lilly A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and the authorities’ approach to reform. You came to Turkey in October after more than four years in China. What is your…

Lilly Huzur Devletsah, General Manager of the Gulf and Near East regions of Lilly, talks about the political instability in other parts of the region, the lack of an adequate talent pool in the industry, and what this all means for the future growth of Lilly.   With the inauguration of…

Contract Manufacturing Lilly set up in Ireland three decades ago by purchasing a farm. In its early days, the operation produced intermediaries for small-molecule drugs. Nearby, Pfizer was manufacturing citric acid for soft drinks. The country was a fledgling industrial economy that was still mostly reliant on sectors like agriculture and fishing.…

Ireland   “The elements that have made Ireland attractive for decades are still here. The big difference since 2007, however, is the cost base. If you are building a pharma plant in Ireland today, it will cost 35 to 40 percent less than it did six years ago,” says Barry O’Leary,…

Lilly As a top 10 global MNC, how does Lilly’s Indonesian affiliate compare with the group’s global positioning? Lilly Indonesia’s position is a bit behind our desired global positioning, but it is appropriate when you consider that Lilly has only started to invest in Indonesia recently. What we see is a…